Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

NCT03045120 · clinicaltrials.gov ↗
COMPLETED
Status
118
Enrollment
INDUSTRY
Sponsor class

Conditions

Sponsor

Bristol-Myers Squibb